Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.
2.

Design, synthesis, antiviral, and cytostatic evaluation of novel isoxazolidine analogues of C-nucleotides.

Grabkowska-Drużyc M, Balzarini J, Piotrowska DG.

Nucleosides Nucleotides Nucleic Acids. 2013;32(12):682-99. doi: 10.1080/15257770.2013.851794.

PMID:
24328565
3.

Synthesis of 5-isoxazol-5-yl-2'-deoxyuridines exhibiting antiviral activity against HSV and several RNA viruses.

Lee YS, Park SM, Kim BH.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1126-8. doi: 10.1016/j.bmcl.2008.12.103. Epub 2008 Dec 31.

PMID:
19147352
4.

Molecular strategies to inhibit the replication of RNA viruses.

Leyssen P, De Clercq E, Neyts J.

Antiviral Res. 2008 Apr;78(1):9-25. doi: 10.1016/j.antiviral.2008.01.004. Epub 2008 Feb 4. Review.

PMID:
18313769
5.

AG-7088 Pfizer.

Witherell G.

Curr Opin Investig Drugs. 2000 Nov;1(3):297-302. Review.

PMID:
11249711
6.

Base-functionalized carbocyclic nucleosides: design, synthesis, and mechanism of antiviral activity.

Nair V, Zhang F, Ma X, Bonsu E.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):408-23. doi: 10.1080/15257770903044465.

7.

Viral proteases as targets for chemotherapeutic intervention.

Hellen CU, Wimmer E.

Curr Opin Biotechnol. 1992 Dec;3(6):643-9. Review.

PMID:
1369416
8.

The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir.

Lacroix C, George S, Leyssen P, Hilgenfeld R, Neyts J.

Antimicrob Agents Chemother. 2015 Sep;59(9):5814-8. doi: 10.1128/AAC.00534-15. Epub 2015 Jun 8.

9.
10.

Nuclear trafficking of proteins from RNA viruses: potential target for antivirals?

Caly L, Wagstaff KM, Jans DA.

Antiviral Res. 2012 Sep;95(3):202-6. doi: 10.1016/j.antiviral.2012.06.008. Epub 2012 Jun 28. Review.

PMID:
22750233
11.

BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease.

Taylor R, Kotian P, Warren T, Panchal R, Bavari S, Julander J, Dobo S, Rose A, El-Kattan Y, Taubenheim B, Babu Y, Sheridan WP.

J Infect Public Health. 2016 May-Jun;9(3):220-6. doi: 10.1016/j.jiph.2016.04.002. Epub 2016 Apr 16. Review.

12.

The medicinal chemistry of protease inhibitors.

Diederich WE, Wegscheid-Gerlach C.

Curr Top Med Chem. 2010;10(3):231. No abstract available.

PMID:
20374196
13.

Acridones as antiviral agents: synthesis, chemical and biological properties.

Sepúlveda CS, Fascio ML, García CC, D'Accorso NB, Damonte EB.

Curr Med Chem. 2013;20(19):2402-14. Review.

PMID:
23521684
14.

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11000-7.

15.

The enterovirus protease inhibitor rupintrivir exerts cross-genotypic anti-norovirus activity and clears cells from the norovirus replicon.

Rocha-Pereira J, Nascimento MS, Ma Q, Hilgenfeld R, Neyts J, Jochmans D.

Antimicrob Agents Chemother. 2014 Aug;58(8):4675-81. doi: 10.1128/AAC.02546-13. Epub 2014 Jun 2.

16.

Anthracene-based inhibitors of dengue virus NS2B-NS3 protease.

Tomlinson SM, Watowich SJ.

Antiviral Res. 2011 Feb;89(2):127-35. doi: 10.1016/j.antiviral.2010.12.006. Epub 2010 Dec 23.

17.

Control of hepatitis C: a medicinal chemistry perspective.

Gordon CP, Keller PA.

J Med Chem. 2005 Jan 13;48(1):1-20. Review. No abstract available.

PMID:
15633995
18.

A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture.

Raut R, Beesetti H, Tyagi P, Khanna I, Jain SK, Jeankumar VU, Yogeeswari P, Sriram D, Swaminathan S.

Virol J. 2015 Feb 8;12:16. doi: 10.1186/s12985-015-0248-x.

19.

New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CL(pro) inhibitors.

Regnier T, Sarma D, Hidaka K, Bacha U, Freire E, Hayashi Y, Kiso Y.

Bioorg Med Chem Lett. 2009 May 15;19(10):2722-7. doi: 10.1016/j.bmcl.2009.03.118. Epub 2009 Mar 28.

20.

Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses.

Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN.

J Virol. 2014 Jul;88(13):7294-306. doi: 10.1128/JVI.00591-14. Epub 2014 Apr 16.

Supplemental Content

Support Center